PS1186 CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY by Garcia‐Gutierrez, V., Hernandez‐Boluda, J.C., Moiraghi, B., Sacha, E.S. Tomasz, Pavlovsky, C., Grzybowska‐Izydorczyk, O., Correa, J., Lopez, R. Perez, Góra‐Tybor, E.P. Joanna, Garcia, A. Novo, Prendes, S. Osorio, Vallansot, R., Payer, A. Ramirez, Wasilewska, E., Villaespesa, M. Piris, Genovard, C. Boque, Encinas, M. Perez, Velasco, A. Jimenez, Sanchez‐Guijo, F., Collada, M.A. Romo, Casares, M.T. Gomez, Pascual, G. Orti, Duran, M.S., Portero, A., Mata, M.I., Noya, M.S., Caballero, G., Garcia, N., Castro, D. Robles, Ramirez, M.J., Magan, A. Senin, Lakhwani, S., Dominguez, J.M. Alonso, Montero, M.I., Chulvi, M.J. Lis, Ciepłuch, H., Steegman, J.L.

Request full text